Loss AB, Souza AAP, Pitombo CA, Milcent M, Madureira FAV
Ozempic is not recommended for individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (genetic disorders that increase the risk of certain tumours)
In particular, a dual-action combination drug has been developed and approved for use, which is simultaneously an agonist of GLP-1 and GIP receptors tirzepatide The most well-known GLP-1 analog, semaglutide, was first approved in the US in 2017 for the treatment of type 2 diabetes as a subcutaneous injection drug called Ozempic
What are the main side effects and safety considerations
doi: 10.1038/s41380-021-01295-8 18 MacphersonKCooperKHarbourJMahalDMillerCNairnM
It offers hope for healthier aging while avoiding the pitfalls of an overly simplistic, one-size-fits-all approach